Methylprednisolone Pulse Macrolide Therapy for Refractory Mycoplasma Pneumoniae Pneumonia in Children (MPP)

Chongqing Medical University

Status: Terminated

Conditions: Refractory Mycoplasma Pneumoniae Pneumonia

Treatments: Drug: azithromycin; Drug: methylprednisolone

Study type: Interventional

Funder types: Other

Identifiers

NCT01217099

ChiCTR-TRC2

Details and patient eligibility

About

The purpose of this study is planned to investigate whether small doses of methylprednisolone pulse macrolide therapy can relieve symptoms,chest X-rays faster than macrolide alone therapy for refractory mycoplasma pneumoniae pneumonia(MPP) .

Full description

Corticosteroid has been used in adulthood refractory MPP with satisfactory efficacy. But there were few studies about the use of corticosteroid in children with refractory MPP. Lee KY et al indicated oral prednisolone of 1 mg/kg/ day for 1 week be useful for children with severe MPP. Akihiro T et al demonstrated that intravenously administered methylprednisolone at a dose of 30 mg/kg once daily for 3 consecutive days had an efficacious treatment for children with refractory MPP.But the methods of corticosteroid use, such as the dosage, administration route, duration of treatment have not been well understood. So in this study, we planned to investigate whether small doses of methylprednisolone pulse macrolide therapy can relieve symptoms,chest X-rays faster than macrolide alone therapy for refractory mycoplasma pneumoniae pneumonia in a prospective, open-label fashion.

PMID: 11096025 PMID: 18033831 PMID: 10434547 PMID: 16437541 PMID: 18656264

Enrollment: 47 patients

Sex: All

Ages: 3 to 11 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• mycoplasma pneumoniae pneumonia
• prolonged fever and deterioration of radiological findings despite macrolides treatment for 7 days or more.

Exclusion criteria

• chronic cardiac and pulmonary disease
• immunodeficiency
• requiring mechanical ventilation
• with other pathogens detected during pneumonia.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

47 participants in 2 patient groups

methylprednisolone

No Intervention group

Description:

methylprednisolone pulse azithromycin

Treatment:

Drug: methylprednisolone

azithromycin

No Intervention group

Description:

azithromycin

Treatment:

Drug: azithromycin